Literature DB >> 18582814

Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients.

Madhuri M Sopirala1, Amy Pope-Harman, David R Nunley, Susan Moffatt-Bruce, Patrick Ross, Stanley I Martin.   

Abstract

We present 6 cases of multidrug-resistant (MDR) Acinetobacter baumannii pneumonia in lung transplant recipients. All cases were treated with imipenem and/or non-traditional antibiotics, such as tigecycline and colistimethate, and had different microbiologic and clinical outcomes. Prior treatment with broad-spectrum anti-microbial therapy was the single most likely risk factor for the development of infection due to MDR Acinetobacter baumannii. Ideal preventive and therapeutic strategies for this pathogen in lung transplant recipients require further study.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18582814     DOI： 10.1016/j.healun.2008.03.023

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN： 1053-2498            Impact factor:   10.247


  9 in total

1.  Severe infection in a lung transplant recipient caused by donor-transmitted carbapenem-resistant Acinetobacter baumannii.

Authors:  N Martins; I S Martins; W V de Freitas; J A de Matos; A C G Magalhães; V B C Girão; R C S Dias; T C de Souza; F L P C Pellegrino; L D Costa; C H R Boasquevisque; S A Nouér; L W Riley; G Santoro-Lopes; B M Moreira
Journal:  Transpl Infect Dis       Date:  2011-12-14       Impact factor: 2.228

Review 2.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

3.  Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient.

Authors:  G Patel; F Perez; A M Hujer; S D Rudin; J J Augustine; G H Jacobs; M R Jacobs; R A Bonomo
Journal:  Transpl Infect Dis       Date:  2015-02-06       Impact factor: 2.228

4.  Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.

Authors:  Madhuri M Sopirala; Julie E Mangino; Wondwossen A Gebreyes; Beth Biller; Tammy Bannerman; Joan-Miquel Balada-Llasat; Preeti Pancholi
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

5.  Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.

Authors:  Shixing Zhu; Jiayuan Zhang; Zhihua Lv; Peijuan Zhu; Charles Oo; Mingming Yu; Sherwin K B Sy
Journal:  Clin Pharmacokinet       Date:  2022-08-10       Impact factor: 5.577

6.  Lung transplantation for cystic fibrosis.

Authors:  Frederick R Adler; Paul Aurora; David H Barker; Mark L Barr; Laura S Blackwell; Otto H Bosma; Samuel Brown; D R Cox; Judy L Jensen; Geoffrey Kurland; George D Nossent; Alexandra L Quittner; Walter M Robinson; Sandy L Romero; Helen Spencer; Stuart C Sweet; Wim van der Bij; J Vermeulen; Erik A M Verschuuren; Elianne J L E Vrijlandt; William Walsh; Marlyn S Woo; Theodore G Liou
Journal:  Proc Am Thorac Soc       Date:  2009-12

Review 7.  Bacterial infections in lung transplantation.

Authors:  Margaret McCort; Erica MacKenzie; Kenneth Pursell; David Pitrak
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

8.  Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.

Authors:  Ryan K Shields; Cornelius J Clancy; Louise M Gillis; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Gregory A Eschenauer; Brian A Potoski; M Hong Nguyen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

Review 9.  Life-threatening infection in transplant recipients.

Authors:  Daire T O'Shea; Atul Humar
Journal:  Crit Care Clin       Date:  2013-08-08       Impact factor: 3.598
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.